The Fellow on Call: The Heme/Onc Podcast

This week, we talk all about hypercoagulable testing - a very common referral in outpatient hematology. Who do we consider testing on? Who should we encourage not to test? We discuss this and more here. Episode contents: - What are situations in which to consider hypercoaguable testing? - What are situations to avoid doing so? **** Get paid to participate in market research surveys: https://affili...

This week, we kick off a new, highly-anticipated and highly-requested series, covering venous thromboembolism (VTE). In this first episode, we discuss how we make the initial diagnosis and how we approach initial management. As a clinician, you will undoubtedly come across the need to make this decision. This episode and this series will set you up for success! Episode contents: -What is venous th...

This week, we welcome Dr. Amar Kishan to our show to discuss the role of radiation oncology in the management of patients with testicular cancer. As our listeners know by now, the management of patients with testicular cancer spans multiple specialities. We always appreciate hearing from our colleagues about their perspective. Episode contents: - What are important studies to send to radiation onc...

This week, we talk all about disseminated testicular cancer, highlighting our current treatment modalities and why we do what we do. We also cover refractory disease. This episode builds on our prior discussions in Parts 1 and 2, so be sure to check these out if you haven’t already! Episode contents: - A history lesson about how we developed our current risk stratification model - Our current trea...

This week, we continue on our testicular cancer journey, focusing on Stage 1 and 2 disease. If you haven’t done so, we highly recommend checking out Episode 127 for our overview of this disease! Episode contents: - What it the approach to stage 1 seminoma and non-seminoa? Radiation? Chemotherapy? Surgery? - What about stage 2 disease? - What are the pivotal trials that shape today's treatment land...

It’s time for another new series, this time focusing on Testicular Cancer. In this first episode, we lay the foundation for our future discussions and discuss the basics of Testicular Cancer. Episode contents: - What are germ cell tumors? - What are important tumor markers to monitor for germ cell tumors? - Seminoma vs. Non-seminoma - Staging of germ cell tumors - Overview of management ****Get pa...

This week, we round out our AML series with a detailed discussion about the approach to management of relapsed and refractory disease. This has been a VERY long road going through all management of AML. We hope that you have continued to build on our discussions week-to-week. An exciting treatment paradigm that is ever-evolving! Episode contents: - How do we define primary induction failure in AML...

In today’s episode, we discuss how to approach AML treatment for patients who are unfit for intensive therapy. Episode contents: - How do we assess fitness for intensive AML? - What are options for patients who are unfit for intensive chemotherapy for AML? - What are important genetic mutations are important to check for? - What are the key trials that inform our management in this space? - How do...

In today’s episode, we welcome back Dr. Amar Kelkar for part 2 of our two-part discussion on allogeneic transplant. In this episode, we build on our prior discussion regarding transplant, this time focusing on transplant for the treatment of AML. Episode contents: - What are the different conditioning regimens available? - How do we decide which regimen is optimal for our patients? - What is the r...

In today’s episode, we welcome back Dr. Amar Kelkar for part 1 of our two-part discussion on allogeneic transplant. In this episode, we discuss the fundamental approach to patient selection and stem cell source selection. As you all know from this series, allogeneic transplants play a pivotal role in the management of AML. Dr. Kelkar’s pearls of wisdom help make this confusing topic so much more a...

This week, we continue our series focusing on acute myeloid leukemia. In this episode, we talk about maintenance therapies in AML. Episode contents: - A recap of cytarabine consolidation - Why do we do maintenance therapy? - What are hypomethylating agents and how do they work? - Important targeted agents that play a role in maintenance therapy ****This episode is sponsored by our Global Research...

This week, we continue our discussion on consolidation and maintenance therapies for AML, this time highlighting the role of allogeneic stem cell transplants. This episode builds on our prior episode, so if you have not listened to this just yet, we highly recommend doing so! Episode contents: - A recap on approach to AML consolidation - The role of allogeneic transplants - The role of MRD testing...

This week, we move to our next phases of therapy for AML, which are consolidation and maintenance. Be sure to check out our prior episodes for a discussion on initial workup and how we incorporate recurrent genetic abnormalities into how we think about AML. Check out figure 1 from this paper for a helpful diagram! Episode contents: - A recap on approach to AML treatment - Who do we consider for al...

This week, we round out our discussion regarding AML induction, this time focusing on the treatment options in the first line setting. We go through the various options, the dosing strategies, and the data behind them. Be sure to check out parts one and two of this three-part induction discussion, as we continue to build on these concepts! Also, if you have not done so, please do check out our hem...

In this week’s episode, we continue onto part two of our three-part discussion on AML induction, this week focusing on selecting our up-front regimen. Be sure to check out last week’s episode, as this one builds on that one. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation! Episode contents: - What is "7+3"? -...

In this week’s episode, we start our three-part discussion on AML induction, this week focusing on key definitions and an overview of treatment. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation! Episode contents: - What are "blasts"? - If there is concern for AML, then what? - Role of leukapheresis or cytoreduc...

In this week’s episode, we discuss the diagnostic criteria and risk stratification for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), building on our discussion from last week. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation! Episode contents: - A review of what to look at on the bone marrow...

This week, we kick off a new series focusing on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this first episode, we discuss the alphabet soup of premalignant hematologic conditions including CHIP, CCUS, and ICUS, before moving onto MDS and AML in future episodes. Episode contents: - What is CHIP vs. CCUS vs. ICUS? - What is the mechanism of hematopoiesis? - What is clonality...

By popular demand, our next series that we are excited to share with you is on MDS/AML! As we prepare for the release of the first episode next week, let’s throw it back to Episode 019 in our Heme/Onc Emergencies Series and talk about APL! Episode contents: - How do we diagnose APL? - What are characteristic findings of APL? - What is the acute management of this disease? ****Have some time and wa...

This week, we have an INCREDIBLE episode for you. We welcome Titilope Fasipe, MD, PhD, who not only is the Co-Director of the Sickle Cell and Thalassemia Program at Texas Children’s and an Assistant Professor in the Department of Pediatrics at the Baylor College of Medicine, she herself also has sickle cell disease! Dr. Fasipe takes us through her life story, from childhood to now. Conducting...

In this week’s episode, we discuss the management of sickle cell disease in the chronic setting. This is a follow up to episode 111 where we discussed acute management of SCD. And furthermore, this is also in addition to our prior discussion about long-term chronic complications from SCD in episode 110. We highly recommend checking out these prior episodes if you haven’t done so already! Contents:...

In this week’s episode, we discuss the management of acute complications of sickle cell disease including acute pain episodes and acute chest syndrome as well as a discussion of hyperhemolytic syndrome. Contents: - How to manage patients with sickle cell disease presenting for acute pain crises - How to approach management of acute chest syndrome - What is hyperhemolytic crisis? - What is splenic...

In this week’s episode, we discuss chronic complications that can arise in patients with sickle cell disease. The reality is, that unless we have an outpatient clinic or rotate through an outpatient clinic, there is a small chance that we will come across many of these issues. However, screening for and managing these chronic complications can have significant implications on our patients’ lives....

It’s time for another new series, this time focusing on Sickle Cell Disease! In this first episode, we lay the foundation for our future discussions. This episode can be dense, but rest assured we will revisit these concepts and expand on them throughout the series. Contents: - What is hemoglobin? - What is the underlying problem in sickle cell disease genotypically? - Why is the presence of sickl...

This week, we round out our discussion on metastatic colorectal cancer, focusing on more targeted therapies for this disease. If you have not done so already, be sure to check out episode 107 for the first part of our metastatic colorectal cancer discussion. Contents: - What is the role of immunotherapy? - What is the role of BRAF inhibition? - Can we use HER2 targeted therapies? - What is the rol...